Aizen Enters into Collaboration with San Diego Biopharma to Advance Oral Biologics

Source: PRNewswire· August 15, 2026

Multi-program deal with revenue potential of $100 million per target SAN DIEGO, Aug. 15, 2026 /PRNewswire/ -- Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, today announced a multi-program collaboration with a San D…

This story was reported by PRNewswire. Read the full original article:
Read on PRNewswire

More in Business & Funding

View all